SH 09 - Lung Cancer/Thoracic Malignancies - Science Highlights

Presentations

• 12:00am - 12:05am ET

  "No Phase III? No Worries!": Analysis of over 1100 Inoperable Early-Stage Lung Cancer Patients Treated with Either Single- or Three-Fraction SBRT to Reveal a Standard of Care

  Speaker: Gregory Videtic, MD, CM, FRCPC, FACR, FASTRO - Cleveland Clinic, Cleveland Heights
• 09:15am - 09:20am ET

  NRG-CC009: A Phase III Trial of Stereotactic Radiosurgery (SRS) vs. Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Brain Metastases from Small Cell Lung Cancer (SCLC)

  Speaker: Chad Rusthoven, MD - University of Colorado School of Medicine, Aurora
• 09:20am - 09:25am ET

  A Prospective, Randomized Controlled Study on the Time Window of Radiotherapy Combined with Targeted Therapy for Primary Tumor in Stage IV NSCLC

  Speaker: Cheng Hu, MD - Affiliated Hospital of Guizhou Medical University, Guiyang
• 09:25am - 09:30am ET

  Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT): Long-Term Outcomes

  Speaker: Caroline Oska, MD - Montefiore Einstein Comprehensive Cancer Center, Bronx
• 09:30am - 09:35am ET

  Chemoradiotherapy (CRT) Followed By Consolidation Durvalumab (D) In Patients (pts) with Resectable or Borderline Resectable Stage IIB-IIIB NSCLC Who Become Unresectable during Neoadjuvant Treatment (Tx): Results from the Phase 2 MDT-Bridge Study

  Speaker: Andrea Filippi, MD - Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan
• 09:35am - 09:40am ET

  Six-Year Overall Survival of Nivolumab Following Stereotactic Ablative Radiotherapy in Early-Stage Non-Small Cell Lung Cancer: Randomized I-SABR Trial

  Speaker: Joe Chang, MD, PhD, MS, FASTRO - MD Anderson Cancer Center, Houston